Department of Ophthalmology, Boston Children's Hospital, Harvard Medical School; Boston, MA, USA.
Department of Pediatric Neonatology, Brigham and Women's Hospital, Harvard Medical School; Boston, MA, USA.
Semin Perinatol. 2019 Oct;43(6):375-380. doi: 10.1053/j.semperi.2019.05.011. Epub 2019 May 10.
Retinopathy of prematurity treatment modalities have expanded over the years, from cryotherapy to laser therapy and now, anti-vascular endothelial factor (VEGF) therapy by intravitreal injection. Use of anti-VEGF treatment varies regionally and depends on multiple factors including severity and progression of ROP, availability of alternative treatments, experience of the local ophthalmologists, medical status of the infant, and expectations for long-term follow-up. While the advantages and disadvantages of anti-VEGF intravitreal treatment on the eye are relatively well-described, few studies provide information about potential long-term systemic effects of this treatment, which is known to transiently reduce systemic VEGF concentrations.
早产儿视网膜病变的治疗方法多年来不断发展，从冷冻疗法到激光疗法，现在又采用了玻璃体内注射抗血管内皮生长因子（VEGF）治疗。抗 VEGF 治疗的应用因地区而异，取决于多种因素，包括 ROP 的严重程度和进展情况、替代治疗的可用性、当地眼科医生的经验、婴儿的医疗状况以及对长期随访的期望。虽然抗 VEGF 玻璃体内治疗对眼睛的优缺点已经得到了相对充分的描述，但很少有研究提供关于这种治疗可能产生的长期全身影响的信息，已知这种治疗会短暂降低全身 VEGF 浓度。
